Physician profile
Kimi A Prentice
NPI 1467684480
$64,957.11
in general payments reported to CMS, 2019-2025
10 companies · $4,931 in 2025
The $4,931 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $13K · 2023: $19K · 2024: $9,919 · 2025: $4,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $27K · Consulting Fee: $4,000 · Food and Beverage: $2,119 · Travel and Lodging: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $27,000.00 |
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,118.69 |
| Travel and Lodging | $1,173.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $63,900.03 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Amgen INC. | $321.84 | 2025 | Krystexxa |
| Novo Nordisk INC | $241.62 | 2025 | Ozempic |
| Genzyme Corporation | $122.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.32 | 2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $72.83 | 2025 | |
| Vifor Pharma, INC. | $69.22 | 2023 | Korsuva |
| Otsuka America Pharmaceutical, INC. | $19.76 | 2022 | |
| Nxstage Medical, INC. | $19.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimi Prentice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.